Cellectar Biosciences sees cash balance sufficient into 2Q25

The company believes its cash balance as of June 30, 2024 of $25.9M, when combined with the $19.4M raised in July, is adequate to fund its basic budgeted operations into Q2 2025. “With our recent positive data announcement from the CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom’s macroglobulinemia, we remain focused on filing our WM NDA in the fourth quarter of this year,” said James Caruso, CEO. “We anticipate an accelerated six-month NDA review period and continue to prepare for a potential launch of iopofosine in 2025. We look forward to bringing this meaningful therapy to market and establishing iopofosine I 131 as the standard of care for the treatment of relapsed and refractory WM patients.”